Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (451-460 of 1,833) with videos related to

Pageof 184
Sort By:
Mabs|May 24, 2016
A hingeless Fc fusion system for site-specific cleavage by IdeSShabazz Novarra, Luba Grinberg, Keith W Rickert, et al.
Mabs|June 2, 2016
Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanerceptIck Hyun Cho, Nayoung Lee, Dami Song, et al.
Mabs|April 7, 2016
Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineeringJames C Geoghegan, Ryan Fleming, Melissa Damschroder, et al.
Mabs|March 18, 2016
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerJuergen M Schanzer, Katharina Wartha, Ekkehard Moessner, et al.
Mabs|March 18, 2016
OX133, a monoclonal antibody recognizing protein-bound N-ethylmaleimide for the identification of reduced disulfide bonds in proteinsLisa-Marie Holbrook, Lai-Shan Kwong, Clive L Metcalfe, et al.
Mabs|April 16, 2016
Ultrafast and high-throughput N-glycan analysis for monoclonal antibodiesXiaoyu Yang, Sunnie Myung Kim, Richard Ruzanski, et al.
Mabs|February 27, 2016
Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitorRong Deng, Daniela Bumbaca, Cinthia V Pastuskovas, et al.
Mabs|May 29, 2015
Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platformAlex Klarenbeek, Khalil El Mazouari, Aline Desmyter, et al.
Mabs|February 12, 2025
Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular propertiesNilufer P Seth, Rui Xu, Matthew DuPrie, et al.
Mabs|January 20, 2025
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice productionHeather J Bax, Jitesh Chauhan, Alexandra J McCraw, et al.
Pageof 184

Showing results (451-460 of 1,833) with videos related to

Sort By:
Pageof 184
Mabs|May 24, 2016
A hingeless Fc fusion system for site-specific cleavage by IdeSShabazz Novarra, Luba Grinberg, Keith W Rickert, et al.
Mabs|June 2, 2016
Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanerceptIck Hyun Cho, Nayoung Lee, Dami Song, et al.
Mabs|April 7, 2016
Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineeringJames C Geoghegan, Ryan Fleming, Melissa Damschroder, et al.
Mabs|March 18, 2016
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerJuergen M Schanzer, Katharina Wartha, Ekkehard Moessner, et al.
Mabs|March 18, 2016
OX133, a monoclonal antibody recognizing protein-bound N-ethylmaleimide for the identification of reduced disulfide bonds in proteinsLisa-Marie Holbrook, Lai-Shan Kwong, Clive L Metcalfe, et al.
Mabs|April 16, 2016
Ultrafast and high-throughput N-glycan analysis for monoclonal antibodiesXiaoyu Yang, Sunnie Myung Kim, Richard Ruzanski, et al.
Mabs|February 27, 2016
Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitorRong Deng, Daniela Bumbaca, Cinthia V Pastuskovas, et al.
Mabs|May 29, 2015
Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platformAlex Klarenbeek, Khalil El Mazouari, Aline Desmyter, et al.
Mabs|February 12, 2025
Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular propertiesNilufer P Seth, Rui Xu, Matthew DuPrie, et al.
Mabs|January 20, 2025
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice productionHeather J Bax, Jitesh Chauhan, Alexandra J McCraw, et al.
Pageof 184